Search clinical trials for: Glargine insulin

Total 8017 results

Nordsjaellands Hospital
Odense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaborators

Completed

Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (HypoDeg)

Type 1 Diabetes Mellitus | Nocturnal Hypoglycemia | Recurrent Severe Hypoglycaemia

Denmark
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Emory University

Completed

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN™ 4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, United Kingdom, France, Argentina, South Africa, Germany, Slovenia, Netherlands, Romania, North Macedonia, Mexico, Puerto Rico
Nanjing First Hospital, Nanjing Medical University

Unknown

Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus

Type2 Diabetes

China
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Eli Lilly and Company

Completed

A Study of LY3192767 in Healthy Participants

Healthy

Germany
Merck Sharp & Dohme LLC

Completed

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Diabetes Mellitus, Type 2 | Diabetes

Germany
Eli Lilly and Company

Completed

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Germany
Eli Lilly and Company

Completed

A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

Type 2 Diabetes Mellitus

Japan, Taiwan, Korea, Republic of
Eli Lilly and Company

Completed

A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Denmark
Eli Lilly and Company

Completed

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

Diabetes Mellitus, Type 1 | Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics

Type 1 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements

Diabetes Mellitus, Type 1

Germany
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
Merck Sharp & Dohme LLC

Completed

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Type 2 Diabetes Mellitus
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes

India, Serbia, Bulgaria, Australia, Korea, Republic of, Thailand, Turkey, United Arab Emirates, Hungary
University of Palermo

Completed

Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

Diabetes Mellitus

Italy
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Janssen Research & Development, LLC

Completed

Fluoroquinolone Associated Disability

Sinusitis | Urinary Tract Infections | Bronchitis

United States
University of the Highlands and Islands

Completed

The Acute Effects of Commercially Available Drinks on the Endothelial Function of Humans Following a High-fat Meal

Endothelial Dysfunction

United Kingdom
Cairo University

Completed

Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM

Diabetes Mellitus (DM)

Egypt
Sanofi

Completed

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey (EASE)

Type 2 Diabetes Mellitus

Turkey
University of Texas Southwestern Medical Center

Withdrawn

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Type 1 Diabetes

United States
AstraZeneca

Completed

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Diabetes Mellitus

United States, Hungary, Slovakia, South Africa, Poland, Romania
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Spain, Hungary, Mexico, Slovakia, Greece, Argentina, South Africa, Australia
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY3209590 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada
AstraZeneca

Completed

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States, Poland, Mexico, Hungary, Spain, Romania, South Africa, Denmark, Czechia, Sweden
Emory University
Merck Sharp & Dohme LLC

Completed

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

Hyperglycemia | Type 2 Diabetes Mellitus | Hospitalization

United States
Huazhong University of Science and Technology

Completed

Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

Type 2 Diabetes Mellitus

China
Eli Lilly and Company

Completed

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Diabetes Mellitus, Type 2

United States
Emory University
Sanofi

Completed

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

Diabetes Mellitus

United States
Chungbuk National University Hospital

Completed

Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Sanofi

Completed

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan (NEWLAN)

Diabetes Mellitus, Type 2

Jordan
Guillermo Umpierrez, MD
Medical University of South Carolina; Sanofi; Texas A&M University

Completed

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) (Basal-Plus)

Hyperglycemia | Type 2 Diabetes

United States
Pfizer

Completed

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Puerto Rico
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
Emory University

Completed

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients (CABG-D/C)

Poor Glycemic Control

United States
Sanofi

Completed

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist (BRIGHT)

Diabetes Mellitus, Type 2

Israel, Czechia, Greece, Italy, United States, Bulgaria, Croatia, Denmark, France, Hungary, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Type 1 Diabetes Mellitus
Emory University
American Diabetes Association

Completed

ADA Linagliptin in Long Term Care

Diabetes

United States

3

Subscribe